Skip to Main Content

The Newborn Infant chapter includes the new 2015 Neonatal Resuscitation Program (NRP) Guidelines for Neonatal Resuscitation.

The Child Abuse & Neglect chapter includes the use of nucleic acid amplification tests to diagnose sexually transmitted diseases in prepubertal children evaluated for sexual abuse.

The Immunization chapter includes new discussions about how HPV vaccination can prevent cancer, how a newer HPV vaccine protects against additional HPV types, and new discussion about how most parents in the United States choose to vaccinate their children (in 2013, < 1% of young children received no vaccines). Although parents' concerns about vaccines are on the rise, an increasing number of parents are choosing to delay or decline vaccination for their children.

The Poisoning chapter includes new recommendations for evaluation and treatment for common ingestions and exposures in the pediatric population, including pharmaceuticals, household products, and designer drugs.

The Skin chapter includes the use of propranolol for infantile hemangiomas.

The Eye chapter describes how instrument-based vision screening is a novel means of detecting vision-threatening amblyogenic risk factors in preverbal, preliterate, and developmentally delayed children, and is endorsed by the American Academy of Pediatrics.

The Oral Medicine & Dentistry chapter includes preventive dental treatment (fluoride varnish) by physicians for high-risk populations.

The Respiratory Tract & Mediastinum chapter introduces the new cystic fibrosis drug, Orkambi.

The Cardiovascular Diseases chapter includes three–dimensional echocardiography as a new diagnostic addition to noninvasive evaluation of congenital heart disease.

The Gastrointestinal Tract chapter identifies the life-threatening impact of button batteries as startling and significant health care problem.

The Liver & Pancreas chapter identifies two new oral therapies that are available for children with chronic hepatitis B: entecavir for children 3 years or older and tenofovir for children 12 years or older.

The Hematologic Disorders chapter notes that hydroxyurea therapy is now recommended for all children with sickle cell anemia or sickle β-thalassemia.

The Immunodeficiency chapter describes the use of genetic testing in the evaluation of children with immunodeficiency and states of immune dysregulation.

The Endocrine Disorders chapter includes the use of recombinant alkaline phosphatase (asfotase alfa) for the treatment of hypophosphatasia and how it has revolutionized therapy for this disorder.

The Genetics & Dysmorphology chapter includes information on microarray testing and whole exome sequencing.

The Antimicrobial Therapy chapter includes information on antimicrobial stewardship.

And many more!

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.